Data from MHRA (Medicines and Healthcare products Regulatory Agency, UK) - Curated by EPG Health - Last updated 28 February 2017

Indication(s)

Copaxone is indicated for the treatment of relapsing forms of multiple sclerosis (MS).

Copaxone is not indicated in primary or secondary progressive MS.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Hereditary ATTR amyloidosis

Hereditary ATTR amyloidosis

Explore the pathophysiology, epidemiology and multi-system symptoms associated with hereditary ATTR amyloidosis, as well as how to achieve an early and accurate diagnosis.

EPNS 2019 Congress Highlights

EPNS 2019 Congress Highlights

The epgonline.org team is creating daily reports from the 13th European Paediatric Neurology Society (EPNS) Congress, held in Athens, Greece from 17th to 21st September 2019, to bring you coverage of cutting-edge science and advances in clinical care across all fields of paediatric neurology. 

Migraine Knowledge Centre

Migraine Knowledge Centre

The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.

Load more

Related Content

More information

Category Value
Authorisation number PL 10921/0023
Orphan designation No
Date First Approved 07-04-2003
Type POM
Marketing authorisation holder Teva Pharmaceuticals Ltd.